Highest-materiality recent filing
ENDRA raises $3.8M via private placement; believes it regains Nasdaq compliance
Gross proceeds ~$3.8M from sale of 578,387 shares (or prefunded warrants) and 1,156,774 warrants at $6.57 per unit.
ENDRA receives Nasdaq delisting notice for equity falling below $2.5M minimum
Nasdaq notified ENDRA on Apr 20, 2026 that stockholders' equity of $2,260,120 as of Dec 31, 2025 fails the $2.5M minimum.
ENDRA Life Sciences reports FY2025 net loss $7.0M; initiates strategic alternatives review
Net loss for Q4 2025 $3.2M vs $4.2M YoY; full year net loss $7.0M vs $11.5M in 2024.
ENDRA Life Sciences cuts staff, initiates strategic alternatives review; severance costs $51K
Reduced headcount on March 19, 2026; expects ~$51K in severance charges in Q1 2026.
ENDRA Life Sciences authorized shares increased from 20M to 1B; officer exculpation rejected
Authorized common shares increased from 20M to 1B via Certificate of Amendment effective Dec 10, 2025.
ENDRA Life Sciences CTO Resigns, Enters Consulting Agreement; CFO Services Formalized
Michael Thornton resigned as CTO effective Nov 28, 2025; entered Consulting Agreement at $150/hr (first 5 hrs/week) then $100/hr.
ENDRA regains Nasdaq equity compliance after $4.9M offering; adds crypto treasury
Closed Oct 2025 private placement raising ~$4.9M gross via 744,340 shares and warrants.
ENDRA closes $4.9M PIPE, buys $3M in HYPE tokens, launches crypto treasury strategy
Gross proceeds of $4.9M from PIPE; potential additional $9.5M from warrant exercises.
ENDRA raises $4.9M in private placement to launch digital asset treasury strategy
Sold 744,340 shares/pre-funded warrants plus up to 1,488,680 common warrants at $6.57 per unit; $6.81 for director participant.
ENDRA raises $4.9M in private placement to launch digital asset treasury strategy managed by Arca
Gross proceeds of ~$4.9M from sale of 744,340 shares/prefunded warrants and warrants at $6.57 per unit; potential $14.4M if all warrants exercised.
ENDRA Life Sciences receives Nasdaq delisting notice for insufficient stockholders' equity
Stockholders' equity of $1,752,885 as of March 31, 2025, below Nasdaq's $2.5M minimum.
Net loss $1.0M in Q1 2025 vs $2.8M in Q1 2024; operating expenses down 46% to $1.5M.
ENDRA Life Sciences Q4 net loss $4.2M, cash burn cut, pivots to GLP-1 metabolic health
Q4 2024 net loss $4.2M ($1.5M in Q4 2023) includes $2.3M non-cash inventory charge; full-year net loss $11.5M.
ENDRA Life Sciences regains Nasdaq minimum bid price compliance
Received Nasdaq confirmation on Nov 21, 2024 that it meets Listing Rule 5550(a)(2).
ENDRA Life Sciences Q3 net loss $2.4M, operating expenses down 52% YoY, cash $4.7M
Net loss of $2.4M narrowed from $3.1M in Q3 2023; no revenue reported (pre-revenue stage).
ENDRA Life Sciences announces 1-for-35 reverse stock split effective Nov 7, 2024
Board approved a ratio of 1/35 for the reverse stock split authorized by stockholders on Oct 28, 2024.
ENDRA Life Sciences stockholders approve reverse stock split; board sets ratio at 1-for-35
Stockholders approved reverse stock split at Special Meeting on Oct 28, 2024 with 4,241,540 for, 2,792,189 against, 18,228 abstain.
Nasdaq Hearings Panel granted extension until November 20, 2024 to regain compliance with $1.00 minimum bid price for 10 consecutive trading days.
ENDRA Life Sciences appoints new CEO, raises $8M, reduces annual OpEx by $3.1M
New acting CEO Alexander Tokman appointed; CFO Richard Jacroux and Regulatory head Ziad Rouag join.
ENDRA Life Sciences announces 1-for-50 reverse stock split to regain Nasdaq bid price compliance
Reverse split effective Aug 20, 2024; shares outstanding drop from ~72.4M to ~1.4M.
Senior Director of Finance Irina Pestrikova resigned Aug 7; Richard Jacroux appointed Head of Finance & principal financial officer on Aug 8.
Nasdaq notifies ENDRA Life Sciences of delisting due to bid price; company to appeal
Stock closed below $0.10 for 10 consecutive trading days ended July 12, triggering delisting under Nasdaq Rule 5810(c)(3)(A)(iii).
ENDRA Life Sciences prices $8M public offering of common stock and warrants
Gross proceeds ~$8M; offering closed June 5, 2024 with Craig-Hallum as placement agent.
ENDRA Life Sciences completes FDA pre-submission meeting for TAEUS liver device
In-person FDA pre-sub meeting held May 16, 2024, on TAEUS liver device clinical trial design for de novo submission.
Expected Q1 2024 net loss of approx. $2.8M vs. $2.9M in Q1 2023; zero revenue in both quarters.
Received Nasdaq notice on May 3, 2024 for closing bid price below $1.00 for 30 consecutive trading days.
Francois Michelon Resignation On August 12, 2024, ENDRA Life Sciences Inc. (“ENDRA” or the “Company”) and Francois Michelon mutually agreed on Mr. Michelon’s resignation as the Company’s Chief Executive Officer and as a member of the Company’s Board of Directors (the “Board”), effective August 12, 2024.
Appointment of Alexander Tokman as Acting Chief Executive Officer Effective August 13, 2024, the Board appointed Alexander Tokman as the Company’s acting Chief Executive Officer and Chairman.
On August 8, 2024, the Company’s Board of Directors (the “Board of Directors”) appointed Richard Jacroux as Head of Finance.
On August 5, 2024, Irina Pestrikova notified ENDRA Life Sciences Inc. (“ENDRA” or the “Company”) of her resignation as the Company’s Senior Director, Finance, effective August 7, 2024.
Max materiality 0.85 · Median 0.70 · Most common event other_material